GE Healthcare and iBio form new global alliance
GE Healthcare and iBio, a Newark, Del.-based provider of pharmaceutical product applications, have formed a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines.
The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's innovative plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology will continue to play a key role in advancing the iBioLaunch platform.
Financial terms were not disclosed.